Multidrug-resistant pulmonary infection in cystic fibrosis – what does ‘resistant’ mean?

References

1. Aaron S. S. D., Vandemheen K. L., Ferris W. 20 other authors 2005; Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multi-resistant bacteria. Lancet 366:463–471 [CrossRef]
   [Google Scholar]
2. Burns J. L., Van Dalfsen J. M., Shawar R. M. 7 other authors 1999; Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190–1196 [CrossRef]
   [Google Scholar]
3. Burns J. L., Saimon L., Whittier S., Krzewinski J., Liu Z., Larone D., Marshall S. A., Jones R. N. 2001; Comparison of two commercial systems (Vitek and MicroScan WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39:257–260 [CrossRef]
   [Google Scholar]
4. Drenkard E., Ausubel F. M. 2002; Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740–743 [CrossRef]
   [Google Scholar]
5. Falagas M. E., Koletsi P. K., Bliziotis I. A. 2006; The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa . J Med Microbiol 55:1619–1629 [CrossRef]
   [Google Scholar]
6. Foweraker J. E., Laughton C. R., Brown D. F. J., Bilton D. 2005; Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 55:921–927 [CrossRef]
   [Google Scholar]
7. Fyfe J. A. M., Govan J. R. W. 1984; Chromosomal loci associated with antibiotic hypersensitivity in pulmonary isolates of Pseudomonas aeruginosa . J Gen Microbiol 130:825–834
   [Google Scholar]
8. Govan J. R. W. 2002; Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 1:S203–S208 [CrossRef]
   [Google Scholar]
9. Govan J. R. W., Deretic V. 1996; Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia . Microbiol Rev 60:539–574
   [Google Scholar]
10. Hill D., Rose B., Pajkos A. 8 other authors 2005; Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Microbiol 43:5085–5090 [CrossRef]
    [Google Scholar]
11. Lam J., Chan R., Lam K., Costerton J. W. 1980; Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28:546–556
    [Google Scholar]
12. MacGowan A. P., Wise R. 2001; Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48:17–28 [CrossRef]
    [Google Scholar]
13. McGowan J. E. 2006; Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 34:S29–S37 [CrossRef]
    [Google Scholar]
14. Morosini M. I., Garcia-Castillo M., Loza E., Perez-Vasquez M., Baquero F., Canton R. 2005; Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 43:4480–4485 [CrossRef]
    [Google Scholar]
15. Moskowitz S. M., Foster J. M., Emmerson J., Burns J. L. 2004; Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42:1915–1922 [CrossRef]
    [Google Scholar]
16. Moskowitz S. M., Foster J. M., Emerson J. C., Gibson R. L., Burns J. L. 2005; Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56:879–886 [CrossRef]
    [Google Scholar]
17. Sader H., Fritsche T. R., Jones R. N. 2006; Accuracy of three automated systems (MicroScan Walkaway, VITEK, and VITEK2) for susceptibility testing of Pseudomonas aeruginosa against five broad spectrum β -lactam agents. J Clin Microbiol 44:1101–1104 [CrossRef]
    [Google Scholar]
18. Saiman L., Burns J. L., Whittier S., Krzewinski J., Marshall S. A., Jones R. N. 1999; Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 37:2987–2991
    [Google Scholar]
19. Smith A. L., Fiel S. B., Mayer-Hamblett N., Ramsey B., Burns J. L. 2003; Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Chest 123:1495–1502 [CrossRef]
    [Google Scholar]
20. Smyth A. 2005; Multiresistant pulmonary infection in cystic fibrosis – prevention is better than cure. Lancet 366:433–435 [CrossRef]
    [Google Scholar]
21. Spellberg B., Powers J. H., Brass E. P., Miller L. G., Edwards J. E. 2004; Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279–1286 [CrossRef]
    [Google Scholar]
22. Stewart P. S., Costerton J. W. 2001; Antibiotic resistance of bacteria in biofilms. Lancet 358:135–138 [CrossRef]
    [Google Scholar]